Researchers at the new Center for Brain Health at UT Health San Antonio are studying midlife testing for early-onset dementia with blood-based biomarkers to see if they can detect disease activity up ...
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to ...
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...
Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...
LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
People often worry they will get Alzheimer’s disease if their parents did. But engaging in a healthy lifestyle can outweigh ...
A new analysis of data from older Americans indicates that chronic sleep disturbances are associated with a shorter lifespan ...
The gut-brain axis is an intricate communication network between the gastrointestinal tract and the central nervous system.
For 2025-27, the Guangzhou Municipal Health Commission and the civil affairs bureau are running a screening program for the ...
Challenging the brain with new learning, like a new language, may build cognitive reserve and memory confidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results